Stage at diagnosis for children with blood cancers in Australia: Application of the Toronto Paediatric Cancer Stage Guidelines in a population-based national childhood cancer registry

Pediatric Blood & Cancer
Danny R YouldenJoanne F Aitken

Abstract

Information on stage at diagnosis for childhood blood cancers is essential for surveillance but is not available on a population basis in most countries. Our aim was to apply the internationally endorsed Toronto Paediatric Cancer Stage Guidelines to children (<15 years) with acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), Hodgkin lymphoma (HL), or non-Hodgkin lymphoma (NHL) and to assess differences in survival by stage at diagnosis. Stage was defined by extent of involvement of the central nervous system (CNS) for ALL and AML and using the Ann Arbor and St Jude-Murphy systems for HL and NHL, respectively. The study cohort was drawn from the population-based Australian Childhood Cancer Registry, consisting of children diagnosed with one of these four blood cancers between 2006 and 2014 with follow-up to 2015. Five-year observed survival was estimated from the Kaplan-Meier method. Stage was assigned to 2201 of 2351 eligible patients (94%), ranging from 85% for AML to 95% for ALL, HL, and NHL. Survival following ALL varied from 94% (95% CI = 93%-95%) for CNS1 disease to 89% (95% CI = 79%-94%) for CNS2 (P = 0.07), whereas for AML there was essentially no difference in survival between CNS- (77%) and CNS+ disease ...Continue Reading

References

Apr 17, 1999·Journal of Pediatric Hematology/oncology·B O SamuelssonI Márky
Oct 22, 2002·JAMA : the Journal of the American Medical Association·Scott C HowardChing-Hon Pui
May 14, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Ron S SmithSarah S Donaldson
Feb 16, 2005·Cancer·Eva Steliarova-FoucherPeter Kaatsch
May 20, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·UNKNOWN Dutch Childhood Oncology GroupSiebold S N de Graaf
Sep 11, 2008·Journal of the National Cancer Institute·Alan S WayneLee J Helman
Jul 24, 2010·Current Hematologic Malignancy Reports·Mohamed RadhiAlan Gamis
Dec 21, 2012·Pediatric Blood & Cancer·Catherine M BollardUNKNOWN COG Non-Hodgkin Lymphoma Committee
Dec 21, 2012·Pediatric Blood & Cancer·Kara M KellyUNKNOWN COG Hodgkin Lymphoma Committee
Mar 14, 2014·Pediatric Blood & Cancer·Mette LevinsenUNKNOWN Nordic Society of Paediatric Haematology and Oncology (NOPHO)
Sep 10, 2014·Acta Oncologica·Annika EnglundGustaf Ljungman
Aug 26, 2015·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Ching-Hon PuiCharles G Mullighan
Aug 26, 2015·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Smita BhatiaMelissa M Hudson
Mar 22, 2016·Clinical Medicine Insights. Oncology·Chindo HicksGail Megason
Apr 16, 2017·The Lancet Oncology·Eva Steliarova-FoucherUNKNOWN IICC-3 contributors
May 24, 2017·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Naomi WinickWilliam L Carroll
Aug 31, 2017·Pediatric Blood & Cancer·Tanja A Gruber, C Michel Zwaan
Sep 1, 2018·The Lancet Child & Adolescent Health·Joanne F AitkenA Lindsay Frazier

❮ Previous
Next ❯

Citations

Mar 23, 2019·Pediatric Blood & Cancer·Sidharth Totadri, Deepak Bansal
May 21, 2020·Journal of the National Cancer Institute·Marion PiñerosEva Steliarova-Foucher
May 29, 2020·Cancer Epidemiology·Friederike ErdmannJeanette Falck Winther
Jan 13, 2021·International Journal of Cancer. Journal International Du Cancer·Donald Maxwell ParkinJoanne F Aitken

❮ Previous
Next ❯

Related Concepts

Related Feeds

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

B-Cell Lymphoma

B-cell lymphomas include lymphomas that affect B cells. This subtype of cancer accounts for over 80% of non-Hodgkin lymphomas in the US. Here is the latest research.